7/7/2020 8:16:14 AM
Aldeyra Therapeutics Announces NDA Development Plans For RASP Inhibitor Reproxalap In Dry Eye Disease
6/15/2020 8:04:57 AM
Aldeyra Therapeutics Gets Orphan Medicinal Product Designation From EU For ADX-2191 Retinal Disease Program
5/20/2020 7:11:55 AM
Aldeyra Therapeutics Announces Planned Advancement
of New HSP90 Inhibitor ADX-1612
4/14/2020 8:14:34 AM
Aldeyra Announces Positive Top-Line Phase 1 Clinical Trial Results And Clinical Development Plans For ADX-629
3/12/2020 7:20:16 AM
Aldeyra Therapeutics Announces Strategic Prioritization Of Late-stage Ocular Disease Programs
3/12/2020 7:04:36 AM
Aldeyra Therapeutics FY Loss Per Share $2.24 Vs Loss $1.79 Last Year
1/28/2020 8:10:10 AM
Aldeyra Therapeutics Appoints Paul Karpecki To Anterior Segment Scientific Advisory Board
1/21/2020 8:18:25 AM
Aldeyra Therapeutics Announces Enrollment Of First Patient Into
Phase 3 INVIGORATE Trial
12/19/2019 8:06:48 AM
Aldeyra Says First Patient Enrolled In Phase 3 GUARD
Trial For Prevention Of Proliferative Vitreoretinopathy
12/3/2019 7:05:55 AM
Aldeyra Announces Positive Top-Line Results From Part 1 Of Adaptive Phase 3 RENEW Trial In Dry Eye Disease
9/26/2019 8:10:15 AM
Aldeyra Therapeutics To Present Phase 3 ALLEVIATE Trial Results In Allergic Conjunctivitis At AAO 2019
9/24/2019 8:13:06 AM
Aldeyra Therapeutics Gets Fast Track Designation For ADX-2191 For Prevention Of Proliferative Vitreoretinopathy
6/25/2019 7:10:18 AM
Aldeyra Says Statistical Significance Not Achieved For Endpoints In SOLACE Trial